The U.S. FDA has approved two applications for the first generics of Pfizer and Bristol-Myers Squibb's Eliquis tablets, a drug used to reduce stroke risks and pulmonary embolisms.
The agency granted approval of the generic apixaban applications to India's Micro Labs and the UK's Mylan Pharmaceuticals. Apixaban, is designed for patients with nonvalvular atrial fibrillation and those who have undergone hip or knee replacement surgery. It’s also used to treat deep vein thrombosis.
Eliquis generated $8.5 billion of sales for co-marketers Pfizer and BMS in the first three quarters of 2019.
Read the FDA release
